Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × rozanolixizumab × 90 days × Clear all

Phase

Phase 3 3 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

Cisplatin 17 Magnetic Resonance Spectroscopy 14 Carboplatin 14 pembrolizumab 12 Specimen Handling 11 Gemcitabine 9 atezolizumab 8 Pemetrexed 8 Paclitaxel 8 Nivolumab 8 Doxorubicin 8 Bevacizumab 7 Radiation 6 Oxaliplatin 6 Radiotherapy 5 Platinum 5 Ipilimumab 5 Immunoglobulin G 5 Drug Therapy 5 Docetaxel 5 Disulfides 5 Cyclophosphamide 5 Biopsy 5 130-nm albumin-bound paclitaxel 5 1,2-diaminocyclohexaneplatinum II citrate 5 venetoclax 4 Trastuzumab 4 Temozolomide 4 Taxes 4 Radiotherapy, Intensity-Modulated 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06149559 2026-02-27

roMyG

UCB Pharma

Phase 2/3 Recruiting

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡